Blog
Personalized Cancer Peptide Vaccine Shows Remarkable Promise Against Glioblastoma
by Guest Author
In recent years, the cancer treatment landscape has begun shifting toward more personalized approaches. This is important because GMB tumors are heterogeneous i.e. no two individuals' tumors are alike. The results of a recent study in which Dr. Santosh Kesari was a collaborator, published in the August 2024 issue of Nature Communications, offer new hope. The study presents compelling evidence for a peptide vaccine that could extend survival for some GBM patients. Learn more.
Glioblastoma Awareness Day: Confronting the Challenges of a Devastating Brain Tumor
by Zara Jethani
The third Wednesday of each July is Glioblastoma Awareness Day. Glioblastoma (GBM) is a complex and invasive form of brain cancer, presenting difficulties in its treatment. Learn more about GMB, clinical trials and the Cancer Moonshot.
Promising Progress: Rare Spine Cancer Shows Positive Response in Clinical Trial at Providence Saint John’s Health Center’s Cancer Institute
by Guest Author
SANTA MONICA (Dec. 4, 2023) — Promising results of a pilot study at Providence Saint John’s Health Center to treat a rare form of cancer of the spine and skull base were published today by the journal Clinical Cancer Research.
Nature-Themed Psychedelic Therapy for Alcohol Addiction: Promising Findings Using Renowned Filmmaker’s Videos
by Guest Author
Immersive nature videos may enhance psychedelic-assisted therapy for alcohol addiction, according to research by Pacific Neuroscience Institute and renowned filmmaker Louie Schwartzberg.
Trial Results Offer Hope for Improved rGBM Survival Outcomes
by Guest Author
Expert neuro-oncologist Santosh Kesari, MD, PhD, Director of Neuro-oncology at Pacific Neuroscience Institute and Chair and Professor of the Department of Translational Neurosciences at Saint John’s Cancer Institute, published the results from a phase 2 clinical trial for recurrent glioblastoma (rGBM), offering hope for improved survival outcomes and pushing novel treatment one step closer to FDA approval.
PNI Foundation VP Melissa Coleman Builds Up the Neurosciences
by Amelia Garrison
With nearly two decades of nonprofit management and fundraising experience, Melissa B. Coleman, Esq, Vice President of the PNI Foundation (PNIF), is an expert at building programmatic research teams in support of neurosciences.
PNI Founders’ Message 2023
by Daniel F. Kelly
At Pacific Neuroscience Institute® (PNI) we achieved many milestones in 2022 and continue to make positive impacts in neuroscience clinical care, research, and education.
Clinical Trial Results for World’s First Glioblastoma Vaccine
by Amelia Garrison
Renowned neuro-oncologist Santosh Kesari, MD, PhD, is one of the authors of a phase 3 trial that found that the use of an autologous tumor lysate-loaded dendritic cell vaccine (DCVax-L) added to the standard of care (SOC) treatment of both newly diagnosed glioblastoma and recurrent glioblastoma...
Stem Cell Therapy and Brain Health: The Future Is Now
by PNI Experts
Clinical trials using stem cells have shown promising early results as cellular therapies in regenerative medicine, as well as in potential anti-cancer applications. Read more about Dr. Achal Singh Achrol's neurosurgery clinical trials program and this leading-edge technology.
Trials for Patients with Brain Tumors and Difficult Diseases
by Guest Author
Santosh Kesari, MD, PhD, of Pacific Neuroscience Institute is the principal investigator for more than a dozen clinical trials, of which 8 are brain tumor-related. Dr. Kesari is Director of Neuro-oncology at PNI, and Chair and Professor of the Department of Translational Neurosciences at Saint John’s Cancer Institute. He is ranked among the top 1 percent of neuro-oncologists and neurologists in the nation, according to Castle Connolly Medical Ltd, and is an internationally recognized scientist and clinician.
Last updated: August 17th, 2022